An Open-labelled, Bridging Phase Ⅲ Clinical Trial to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine in Healthy Population Aged From 3 to 11 Years
Latest Information Update: 18 Oct 2023
At a glance
- Drugs SARS-COV-2 vaccine-inactivated-Sinovac-Biotech (Primary)
- Indications COVID 2019 infections
- Focus Pharmacodynamics; Registrational
- Sponsors Sinovac Biotech
- 12 Oct 2023 Status changed from active, no longer recruiting to completed.
- 25 Apr 2022 Planned primary completion date changed from 27 Feb 2022 to 27 Jul 2022.
- 13 Dec 2021 Status changed from not yet recruiting to active, no longer recruiting.